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Abstract
Background: After the introduction of novel effective immunosuppressive therapies, kidney transplantation
became the treatment of choice for end stage renal disease. While these new therapies lead to better graft
survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary
pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide
a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of
immunosuppressive regimen and pulmonary complications.
Methods: A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25
to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were
correlated with clinical findings including immunosuppressive medications.
Results: The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell
carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post
transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases),
and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary
alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process.
Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5%
vs. 58.3%, p = 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary
hemorrhage as the sole histological finding or in combination with other patterns.
Conclusions: Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft
recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk
of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/3320012126569395.
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Kidney transplantation is considered the treatment of
choice for end stage renal disease (ESRD), which is in
part due to availability of more effective immunosup-
pressive regimens. The mammalian target of rapamycin
(mTOR) inhibitors, rapamycin, also known as sirolimus,
and everolimus, have been recently widely utilized in
immunosuppressive regimens providing adequate immu-
nosuppression and avoiding nephrotoxic side effects of
calcineurin inhibitor therapy [1-4]. However, prolonged
graft survival leads to increased incidence of complica-
tions related to both immunosuppression and drug toxi-
city. Drug induced immunosuppression halts tumor
surveillance leading to an increase in tumor develop-
ment. Epidemiologic studies show that posttransplant
lymphoproliferative disorder (PTLD) and skin cancers
increased most dramatically following kidney transplan-
tation [5-8]. In addition to immunosuppression, siroli-
mus exhibits antineoplastic properties in vivo [9] and
newer rapamycin analogs have been evaluated in clinical
trials for treatment of renal cell carcinoma [10]. Clinical
experience with these medications is limited; but it has
been shown to cause regression of PTLD and Kaposi
sarcoma [11-14]. The incidence of pulmonary toxicity in
patients on mTOR inhibitors has been reported to be
up to 11% [15,16]. Risk factors for the development of
sirolimus-associated pneumonitis include higher dose,
greater trough levels and older age [17]. While the con-
tribution of other causes in the setting of mTOR inhibi-
tor induced immunosuppression is difficult to separate
from direct drug toxicity, a range of pulmonary histo-
pathologic changes has been suggested as manifestations
of drug toxicity. Depending on biopsy modality these
include descriptive diagnoses or better-defined histologi-
cal patterns such as organizing pneumonia and diffuse
alveolar hemorrhage [15,16,18-20]. Pulmonary hemor-
rhage has been reported as a sole histological finding
[21] but also in combination with others [18]. Other
rare pulmonary manifestations include pulmonary alveo-
lar proteinosis [22], desquamative interstitial pneumoni-
tis [23], hypersensitivity pneumonitis [24], necrotizing
granulomas and vasculitis [25], diffuse alveolar damage
[26] and non-necrotizing granulomas [19]. Since the
reported histological manifestations are not specific for
sirolimus toxicity, drug discontinuation with or without
steroid therapy is the mainstay of treatment in suspected
cases and typically leads to resolution of symptoms
within 2 to 4 months [18]. To the best of our knowl-
edge, only small series or case reports describe pulmon-
ary pathology in renal allograft recipients and the
concept of sirolimus-associated pulmonary complica-
t i o n si ss t i l le v o l v i n g .T h e r e f o r e ,t h eg o a l so ft h i ss t u d y
were to provide a systematic review of pulmonary
histological findings in the setting of kidney transplanta-
tion and elucidate the possible contribution of the cur-
rent immunosuppressive regimens to the spectrum of
the observed histological changes.
Material and methods
A laboratory information system database search from
January 2002 to September 2010 revealed 28 renal allo-
graft recipients who required a lung biopsy for respiratory
symptoms. In total, 42 biopsies were performed, including
8 (19%) video-assisted thoracoscopic biopsies, 28 (67%)
endobronchial biopsies, 5 (12%) needle biopsies, and 1
(2%) mediastinal lymph node biopsy. Sixteen (38%) biop-
sies were nondiagnostic. Biopsies were considered non-
diagnostic if they had limited tissue or minimal nonspeci-
fic histological changes such as chronic inflammation or
focal interstitial fibrosis. Hematoxylin-eosin (H&E) stained
slides (range, 1-19; mean, 3 slides) and special stains for
microorganisms including Gomori methenamine silver,
Ziehl-Neelsen and gram stains, performed on formalin-
fixed, paraffinembedded tissue were re-examined. The
radiology studies including chest computed tomography
(CT) were reviewed in respect to localized versus diffuse
changes. Localized lesions included nodules or masses
while the diffuse lesions were comprised of diffuse or pat-
chy bilateral ground glass opacities, reticular densities,
bilateral consolidations, mosaic attenuation, and traction
bronchiectasis. Retrospective analysis of electronic clinical
records and correlation with histological findings and type
of immunosuppressive therapy were performed. The elec-
tronic medical records were reviewed with special atten-
tion for evidence of systemic diseases and infectious
complications including microbiological cultures and
serologies for viral and fungal pathogens. Review of immu-
nosuppressive regimens included an active list of medica-
tions pre-and post-lung biopsy. Clinical and pathological
findings were analyzed utilizing mean ± SD for continuous
variables, and number or percentage for categorical vari-
ables. Comparisons were performed using Yates’ chi-
square test for categorical variables, and the two-sample t
test for continuous variables. The study was approved by
The Ohio State Biomedical Sciences Institutional Review
Board in compliance with Health Insurance Portability
and Accountability Act regulations.
Results
Clinicopathological findings in patients with kidney
transplant
The main clinical and pathological findings are summar-
ized in Table 1. Twenty-eight of 2140 (1.3%) kidney
transplant recipients over the period of 105 months
underwent a lung biopsy for pulmonary symptoms.
They included 18 males and 10 females with an age
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Page 2 of 10Table 1 Clinical pathological findings in kidney transplant recipients
Age,
years
Gender Kidney
disease
Transplant
type
Time,
mos
Sirolimus trough
levels, mean
(range), ng/ml
Other
immuno-
suppressants
Clinical radiological
presentation
Biopsy
type
Pathological
findings
1* 49 M** DM1 K/Cad 11 11.7(6.2-18.7) C/P Bilateral mass-like
consolidations
EB ND
2 25 F DM1 K/Cad 20 C/MY/D Patchy bilateral consolidations EB BCLPD
3 71 M PCKD K/Cad 36 C/D Mediastinal lymphadenopathy EB LNB DLBCL
4 58 F DM2 K/Cad 5 8.8(4.0-17.1) C/P Respiratory failure Diffuse
ground glass opacities
EB THB Hemorrhage
5 47 F HTN K/Cad 210 C/MY/P Respiratory failure, loculated
pneumonia
EB Necrosis
Fibrin
6 72 M DM2 K/Cad 20 4.8(2.0-8.2) C/P Spiculated lung lesion NB SQC
7 77 M K/Cad 116 C/D Pulmonary nodule EB SQC
8 71 M pANCA K/Cad 10 15.1 C/P Right lower lobe mass EB ND
Diffuse ground glass opacities
9 48 F NA K/Cad 32 NA MY/P Left lower lobe nodule EB Necrosis
Fibrin
10 39 M GN K/Cad 80 10.2(8.1-11.8) C/P Respiratory failure, diffuse
ground glass opacities with
crazy paving pattern
THB
EB
Hemorrhage
PAP
OP
11 45 F NA K/Cad, LR 345 C/P Collapsed lung, pneumonia EB OP
12 58 F HTN K/Cad 24 19.7 C/P Respiratory failure, diffuse
ground glass opacities
EB THB Hemorrhage
13 44 F DM2 K/LR 36 5.3(3.2-6.9) C/P Mediastinal lymphadenopathy,
patchy ground glass opacities
EB ND
14 46 M WG K/LR 175 C/MY/P Diffuse ground glass opacities,
lung nodules
EB
NB
Hemorrhage
Capillaritis
15 49 F DM K 73 8.1(4.3-11.6) C/P Bilateral ground glass
opacification with right lower
lobe consolidation
EB OP
16 34 F DM1 KP/Cad 19 4.2(2.4-6.7) C/P Respiratory failure, diffuse
ground glass opacities
THB DAD
Hemorrhage
17 43 M DM1 KP 41 4.4 C/P Nodular right lower lobe
infiltrate
EB ND
18 69 M DM2 K/LU 4 11.0(5.0-14.9) C/P Bilateral lung nodules and
mediastinal lymphadenopathy
NB BCLPD
19 71 M IgA K/LR 114 C/P Dyspnea, diffuse ground glass
opacities
EB PAP
20 60 M GN K/LR 89 C/MY/D Lung nodule EB ND
21 65 M K/LR 41 6.8(2.8-12.0) MA/P Bilateral hypermetabolic lung
nodules
THB PJ
granulomas
22 60 M GN K/LR 66 C/P Lung mass THB ADC
23 52 M DM1 KP/Cad 73 C/P Lung mass EB SQC
24 34 M GN K/Cad 38 10.2(6.1-14.3) C/P Bilateral ground glass opacities
Loculated right sided pleural
effusion
EB Fibrin
Necrosis
25 36 F NA K 180 C/P Bilateral lung nodules,
lymphadenopathy
THB NB LYG
26 62 M IN K/LR 115 C/P Lung mass NB ADC
27 53 M PCKD K/LU 61 2.0 MA/P Lung nodule, pleural effusion EB ND
28 32 M CR K/LU 220 8.6(4.4-13.2) C/MA/P Dyspnea, patchy ground glass
opacities
EB OP
(*) - the cases are arranged in chronological order; (**)-M male; F female; DM diabetes mellitus; PCKD polycystic kidney disease; HTN hypertension; p-ANCA p-
ANCA vasculitis; GN glomerulonephritis; WG Wegner’s granulomatosis; IgA IgA nephropathy; IN interstitial nephritis; CR chronic reflux; K kidney transplant; KP
kidney and pancreas transplant; Cad cadaveric kidney; LR living related kidney; LU living unrelated kidney; EB endobronchial biopsy; THB thoracoscopic biopsy; NB
needle biopsy; LNB lymph node biopsy; C cyclosporine; P prednisone; D dexamethasone; MY mycophenolate mofetil; MA mycophenolic acid; ND not diagnostic;
SQC squamous cell carcinoma; ADC adenocarcinoma; BCLPD B-cell lymphoproliferative disorder; DLBCL diffuse large B-cell lymphoma; LYG lymphomatoid
granulomatosis; OP organizing pneumonia; DAD diffuse alveolar damage; PJ Pneumocystis jiroveci; PAP pulmonary alveolar proteinosis; NA not available
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The time from kidney transplantation to lung biopsy
ranged from 4 to 345 months (mean 81 months). In 19
cases (68%) the biopsies were performed to obtain tissue
diagnosis for localized lesions, and in 9 cases (32%) for
diffuse lesions. The majority of patients (18/28 or 64%)
received a deceased donor kidney. Eight patients (29%)
received kidneys from living related donors; two patients
(7%) received kidneys from living unrelated donors. One
patient received three transplants, including two cadave-
ric and one living related. Twenty-five (89%) patients
had kidney-only transplant, while three patients (11%)
had a combined kidney and pancreas transplantation.
The most common cause of ESRD was diabetic nephro-
pathy (10/28; 36%). Other causes included hypertension
(2/28; 7%), polycystic kidney disease (2/28; 7%), glomer-
ulonephritis (4/28; 14%), granulomatosis with polyangii-
tis (Wegner’s granulomatosis) (1/28; 4%), IgA
nephropathy (1/28; 4%), chronic reflux (1/28; 4%), p-
ANCA-positive microscopic polyangiitis (1/28; 4%), and
interstitial nephritis (1/28; 4%).
Neoplasia on lung biopsy was identified in 9 (0.4%) of
2140 kidney transplant recipients. Among 9 cases there
were 5 non-small cell carcinomas and 4 PTLD. Non-small
cell carcinomas included 3 cases of squamous cell
carcinoma and 2 cases of adenocarcinoma (Figure 1A).
PTLD included 1 case of diffuse large B-cell lymphoma, 1
case of lymphomatoid granulomatosis (Figure 1B-C) and 2
cases of post transplant B-cell lymphoproliferative disor-
ders. Diffuse parenchymal lung disease was identified in 9
(0.4%) cases. In 2 cases, pulmonary hemorrhage (PH) was
the sole histological finding. In 1 case PH was associated
with capillaritis. In 1 case PH was associated with pulmon-
ary alveolar proteinosis (PAP) and in 1 case with diffuse
alveolar damage (DAD). PH associated with capillaritis
was documented in a patient with WG and was consid-
ered a pulmonary manifestation of the disease. Organizing
pneumonia (OP) as the main histological finding was iden-
tified in 3 cases and PAP was identified in 1 case. Five
(0.2%) cases showed histological features indicative of an
infectious process including tissue necrosis, necrotic cellu-
lar debris, acute inflammation, and granulomas. In 1 of 5
cases, granulomatous inflammation was associated with
Pneumocystis jiroveci (Figure 1D). Lung biopsy showed
minimal findings in 5 (0.2%) patients.
Clinicopathological findings in patients on sirolimus
All patients with a lung tissue diagnosis received com-
bination immunosuppressive therapy. The immunosup-
pressive regimen of 16 of 28 (57%) patients included
Figure 1 Neoplastic and non-neoplastic localized lesions in renal transplant recipients. (A) adenocarcinoma with predominantly
micropapillary pattern (case 22, hematoxylin-eosin, original magnification x200); (B) lymphomatoid granulomatosis showing angiocentric
proliferation of atypical lymphoid cells associated with Epstein-Bar virus (C), (case 25, hematoxylin-eosin and colorimetric in situ hybridization,
original magnification x200 and x400, respectively); necrotizing granuloma (D) associated with Pneumocystis jiroveci (case 21, hematoxylin-eosin
and Gomori methenamine silver, inset, original magnification x100 and x600, respectively).
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Page 4 of 10sirolimus (Table 2). Other immunosuppressants were
comprised of cyclosporine (25/28; 89%), prednisone
(23/28; 82%), dexamethasone (4/28; 14%), mycopheno-
late mofetil (6/28; 21%), and mycophenolic acid (2/28;
7 % ) .T h eg r o u p so fp a t i e n t sr eceiving sirolimus versus
other immunosuppressive medications were of similar
age and gender (Table 2). However, the mean time
from the transplant to lung biopsy of patients on siro-
limus was shorter (44.7 ± 52.04 vs. 128.3 ± 89.32, p =
0.01). Patients on sirolimus less frequently than
patients on other immunosuppressants had neoplasia
(12.5% vs. 58.3%, p =0 . 0 3 ) .T u m o r si np a t i e n t so ns i r -
olimus included 1 squamous cell carcinoma and 1 post
transplant B-cell lymphoproliferative disorder. Tumors
in the non-sirolimus group included 2 adenocarcino-
mas, 2 squamous cell carcinomas, 1 posttransplant B-
cell lymphoproliferative disorders, 1 diffuse large B-cell
lymphoma and 1 lymphomatoid granulomatosis.
Patients on sirolimus had a tendency to have diffuse
parenchymal lung disease (37.5% vs. 25.0%), including
hemorrhage (25.0% vs.8.3%). The results, although sug-
gestive of an association, did not achieve statistical
significance.
Sirolimus toxicity and response to treatment modification
Sirolimus toxicity was suspected clinically in 5 (31.3%)
of 16 patients. Their mean trough sirolimus levels were
not statistically different from the other 10 cases on sir-
olimus (10.3 ± 5.72 ng/ml vs. 7.6 ± 3.56 ng/ml). Among
these 5 cases, lung biopsies in 4 revealed pulmonary
hemorrhage and OP, in 1. All 5 patients showed clinical
and radiological improvement after the drug
discontinuation. Their clinical course and response to
treatment modification is detailed below.
In case 4, a 54 year old woman was admitted with
recurrent shortness of breath for the fourth time in the
five months following kidney transplant. The patient
had a past medical history of chronic obstructive pul-
monary disease and congestive heart failure with basic
oxygen requirements of 3-4 l via nasal cannula. On her
current admission she was in severe respiratory failure,
requiring mechanical ventilation. Her trough sirolimus
levels following transplantation were within range from
4.0 to 17.1, (mean, 8.8), normal 3-20 ng/ml. A chest CT
on admission showed diffuse ground glass opacities and
pleural effusions. Endobronchial biopsy was nondiagnos-
tic, while a subsequent open lung biopsy showed collec-
tions of hemosiderin laden macrophages occupying
alveolar spaces as well as hemosiderin granules within
interstitium (Figure 2A). Evaluation for infectious organ-
isms and vasculitis was negative. Since treatment for
infection did not produce any significant improvement,
sirolimus toxicity was suspected and sirolimus was dis-
continued. The patient returned to baseline respiratory
status (3-4 l of oxygen) with improvements in bilateral
opacities radiologically within 6 months. Following dis-
charge, the patient required a single readmission for
respiratory symptoms over the subsequent 33 months.
At that time she was admitted for respiratory failure
and subsequently expired. Postmortem examination
revealed extensive hemosiderin deposition and a left
upper lobe adenocarcinoma.
Case 10 is that of a 39-year-old African-American
male, 80 months post kidney transplantation,
Table 2 Clinicopathological findings in patients on sirolimus versus other immunosuppressive therapy
Sirolimus n = 16 Non-Sirolimus n = 12 P, value
Age, mean, years 51.1 ± 13.25 54.3 ± 15.39 ns
Gender, M* 10 (62.5) 8 (66.7) ns
F 6 (37.5) 4 (33.3) ns
Time to lung biopsy, mean, months 44.7 ± 52.04 128.3 ± 89.32 0.01
Neoplasia, total, n (%) 2 (12.5) 7 (58.3) 0.03
Carcinoma, n (%) 1 (6.25) 4 (33.3) ns
Lymphoproliferative disorders, n (%) 1 (6.25) 3 (25.0) ns
Diffuse parenchymal lung disease, n (%) 6 (37.5) 3 (25.0) ns
PH, n (%) 2 (12.5) 1 (8.3) ns
PH and DAD, n (%) 1 (6.25) 0 -
PH and PAP, OP, n (%) 1 (6.25) 0 -
OP, n (%) 2 (12.5) 1 (8.3) ns
PAP, n (%) 0 1 (8.3) -
Necrosis/infectious granulomas, n (%) 4 (25.0) 1 (8.3) ns
Minimal histological findings, n (%) 4 (25.0) 1 (8.3) ns
(*) -M male; F female; PH pulmonary hemorrhage; DAD diffuse alveolar damage; PAP pulmonary alveolar proteinosis; OP organizing pneumonia; ns, not
statistically significant
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Page 5 of 10Figure 2 Pathological findings in patients with sirolimus toxicity. In case 4, open lung biopsy shows diffuse alveolar hemorrhage
represented by collections of hemosiderin laden alveolar macrophages (A, inset) and occasional hemosiderin granules within interstitium,
(hematoxylin-eosin, original magnification x100 and x400, respectively). In case 10, open lung biopsy shows pulmonary hemorrhage in
association with pulmonary alveolar proteinosis and organizing pneumonia: there are areas with hemosiderin deposition within interstitium (B)
and cholesterol granulomas, finely granular proteinaceous material with cholesterol clefting (C) and foci of organizing pneumonia (D) in adjacent
alveolar parenchyma, (hematoxylin-eosin, original magnification x100, x200 and × 40, respectively). Computed tomography of the chest at the
time of open lung biopsy shows diffuse ground glass and “crazy pavement” opacities (E). Follow up computed tomography in 8 months (F)
shows marked decrease in alveolar opacities; both scans are at the level of aortic arch for comparison. In case 16, open lung biopsy shows a
combination of diffuse alveolar damage and pulmonary hemorrhage: there are edematous alveolar septae lined by hyaline membranes (G) and
hemosiderin-laden macrophages (H) within alveolar spaces (H&E, original magnification x200 and x400, respectively).
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increasing creatinine levels. His progressive hypoxia
resulted in intubation. A chest CT showed diffuse bilat-
eral ground glass opacities, “crazy pavement” pattern
and focal nodular consolidation. His trough sirolimus
levels within 6 months prior to admission were 8.1-11.8,
(mean, 10.2) normal, 3-20 ng/ml. Hemosiderin laden
macrophages associated with rare cholesterol granulo-
mas were seen on transbronchial biopsy. His respiratory
status continued to deteriorate and open lung biopsy
was performed that showed alveolar and interstitial
hemosiderin deposition accompanied by patchy organiz-
ing pneumonia, cholesterol granulomas and eosinophilic
proteinaceous granular material (Figure 2B-D). The find-
ings were compatible with a combination of PH and
PAP. He underwent therapeutic bronchioloalveolar
lavage and the decision was made to discontinue all
immunosuppressive medications other than prednisone.
During his nearly 2 month hospital stay, he was gradu-
ally weaned from ventilation support and his oxygen
requirement at the time of discharge was 2 l of oxygen.
Over the ensuing 8 months he showed clinical and radi-
ological improvement (Figure 2E-F) on mycophenolate
maintenance therapy. At 3.5 years of follow up, the
patient was on maintenance mycophenolate therapy,
had intermittent problems with recurrent lower respira-
tory tract infections, residual restrictive lung disease,
and continued to use 2-3 l of oxygen via nasal cannula
mostly with exercise.
Case 12 represents a 58-year old female who was hos-
pitalized 24 months post kidney transplantation with
shortness of breath, hypoxia, and renal failure. Her
trough sirolimus level before admission was elevated to
19.7 ng/ml, normal 3-15 ng/ml. A bronchoscopic biopsy
revealed occasional hemosiderin granules. Her symp-
toms did not improve and an open lung biopsy revealed
histological evidence of PH with alveolar and interstitial
hemosiderin deposition. Respiratory and blood cultures
remained negative throughout the patient’s stay. Siroli-
mus was stopped and over the following 4 months she
showed significant clinical improvement despite contin-
ued baseline oxygen requirements.
Case 16 is that of a 34-year old female who was
admitted in respiratory failure 17 months post kidney-
pancreas transplant with two episodes of acute rejection.
Her trough sirolimus levels were within range 2.4-6.7
ng/ml, mean 4.2 ng/ml, normal 3-15 ng/ml. Hemosi-
derin laden macrophages were present in the bronch-
ioalveolar lavage fluid. Sirolimus toxicity was suspected
and sirolimus was discontinued. Despite extensive work-
up for infectious and rheumatologic etiologies and treat-
ment with wide spectrum antibiotics she remained in
respiratory failure. An open lung biopsy showed a com-
bination of DAD and PH with hyaline membranes,
architectural simplification with alveolar septal collapse,
diffuse myxoid thickening, type 2 pneumocyte hyperpla-
sia, and alveolar and interstitial hemosiderin (Figure 2G-
H). The patient’s treatment also included mechanical
ventilation, volume and blood pressure control. After 2
months at a rehabilitation facility, her shortness of
breath and cough were significantly improved and chest
CT revealed resolution of the bilateral infiltrates. On
further follow-up, the patient reported minimal respira-
tory symptoms.
Case 28 represents a 31-year-old male, 220 months
post kidney transplantation, started to experience cough
and dyspnea. He received a course of antibiotics for
community-acquired pneumonia with no improvement.
His trough sirolimus levels within previous 6 months
were 4.4-13.2 ng/ml, (mean 8.6 ng/ml), normal 5-30 ng/
ml. He underwent an extensive evaluation including a
CT scan of the chest revealing extensive ground glass
densities in a multifocal distribution. Evaluation for col-
lagen vascular disease and infectious etiologies were
negative, including a bronchoscopic examination with
microbiological cultures. Transbronchial lung biopsy
showed patchy organizing pneumonia and chronic
inflammation. Since no systemic or infectious causes for
his symptoms were found, sirolimus toxicity was sus-
pected. Sirolimus was discontinued and he was given a
course of oral corticosteroids. Over the following 2
months, his respiratory status improved significantly,
with no reported shortness of breath, cough or wheezing
and discontinuation of supplemental oxygen.
Discussion
Kidney transplant recipients are known to be at
increased risk for malignancy with up to 2 fold
increased incidence rates for lung cancer and 20-fold
increased incidence rates of PTLD [5]. Our retrospective
review shows a wide spectrum of neoplastic and non-
neoplastic lesions in the lungs of kidney transplant reci-
pients on current immunosuppressive regimens. Among
the neoplastic lesions there were 5 cases of non-small
cell lung carcinoma and 4 cases of PTLD with incidence
of approximately 0.2% each. The incidence of lung carci-
noma in our series was similar to what was previously
reported in other single center cohorts [27,28], exceed-
ing the incidence seen in general population [5]. The
incidence of PTLD was lower, which is likely due to the
fact that our study examined only lung biopsies and
therefore couldn’t account for the PTLD involving other
sites. PTLD reportedly affects 1.8% of patients with up
to 50% of cases presenting with extranodal masses,
including lung nodules [29-31].
When correlated to the type of immunosuppression,
the frequency of neoplasia in patents on sirolimus was
lower (12.5% vs. 58.3%, p = 0.03) relative to patients on
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Page 7 of 10other immunosuppressants. It is possible that the longer
transplant to lung biopsy time in the non-sirolimus
group may have contributed to increased tumor detec-
tion. Nevertheless, our findings are in agreement with
studies supporting antineoplastic properties of mTOR
inhibitors in pre-clinical testing [9,32,33] and clinical
studies of patients with post transplant solid organ
tumors [28,34-36], suggesting that sirolimus may be
beneficial in preventing posttransplant malignancies.
Our study also demonstrates that pulmonary hemor-
rhage is a common histological finding in cases with
clinically suspected sirolimus toxicity. In this cohort, it
can be seen as the sole histological finding or in com-
bination with other histological patterns including
DAD and PAP. Based on their own experience and
review of the literature, Pham and colleagues list pul-
monary hemorrhage, organizing pneumonia, and lym-
phocytic pneumonitis among the most common
histological patterns of sirolimus toxicity [18]. From a
clinical management point of view, the histological
diagnosis of pulmonary hemorrhage carries a task of
elucidating its possible causes which generally include
alveolar hemorrhage syndromes or secondary causes
associated with infections, toxic inhalation, coagulopa-
thies, renal failure with volume overload, and venous
congestion due to heart disease to name a few [37]. In
our series only one case with PH was linked to Wege-
ner’s granulomatosis. During their clinical course, the
study patients experienced renal failure with wide fluc-
tuation of serum creatinine levels; however, the renal
function was generally well controlled, and none had
clinically documented sustained fluid overload. In our
cases pulmonary hemorrhage could not be explained
by any other causes, and sirolimus discontinuation lead
to the gradual clinical improvement. In case 4, the
patient had congestive heart failure, which histologi-
cally can be associated with pulmonary hemosiderin
deposition. Therefore, it is difficult to completely
exclude the contribution of the patient’su n d e r l y i n g
heart disease to the observed histological findings. In
that regard, this case is similar to that reported by
Hashemi-Sadraei N and colleagues [38]. They
described a renal transplant recipient who was on
c h r o n i ca n t i c o a g u l a t i o nt h e r a p yf o rap r o s t h e t i ca o r t i c
valve, and who developed pulmonary symptoms follow-
ing initiation of sirolimus therapy. An open lung
biopsy showed diffuse alveolar hemorrhage with fibrin
deposits in the alveolar spaces and small bronchi. Even
though the underlying disease, congestive heart failure
or heart valve requiring anticoagulation therapy, may
have contributed to the pulmonary hemosiderin
deposition, in both of these cases the response to siro-
limus discontinuation suggests a causative association
between the drug and pulmonary hemorrhage.
Other histological patterns identified within a spec-
trum of the diffuse parenchymal lung disease in patients
on sirolimus were OP, DAD, and PAP. The spectrum of
etiologic considerations in OP includes infection, col-
lagen vascular disease, toxic inhalation, aspiration pneu-
monia, hypersensitivity pneumonitis, and drug toxicity
[39,40]. Additionally, OP can be a minor component of
other interstitial lung diseases. OP is one of the rela-
tively frequently reported manifestations of sirolimus
toxicity [18]. We identified OP as a main histological
feature in 3 cases; however, it was also observed as a
minor component in other cases including cases of pul-
monary hemorrhage and DAD. This could be a reason
for some discrepancy between reported frequencies of
OP, especially if a diagnosis is rendered on a small
endobronchial or transbronchial biopsy [18]. DAD is a
well recognized histological pattern known to be asso-
ciated with drug toxicity [41]. Among tissue reactions
associated with sirolimus toxicity, only one case of DAD
has been documented in the literature. Manito and col-
leagues [26] reported a fatal course of DAD in a 52-
year-old man heart transplant recipient following a load-
ing-dose of sirolimus administration. We observed DAD
i no n ep a t i e n to ns i r o l i m u s( c a s e1 6 )w h e r ea no p e n
lung biopsy revealed a combination of DAD and pul-
monary hemorrhage. No infectious or systemic disease
was documented with extensive clinical evaluation.
Despite wide spectrum antibiotics coverage, the patient
showed a protracted clinical course but gradually
improved over 2 months after sirolimus discontinuation
showing only minimal pulmonary symptoms.
PAP is a rare poorly understood disorder that is char-
acterized by accumulation of lipoproteinaceous surfac-
tant-like material within alveolar parenchyma. Impaired
macrophage function due to antibodies to granulocyte
macrophage-colony stimulating factor is thought to be a
key mechanism in primary PAP. Macrophage dysfunc-
tion due to immunosuppression is considered as one
among many other causes of secondary PAP. It has
been linked to sirolimus toxicity in 2 previously reported
cases [22,42]. PAP histology in our series was documen-
ted in both sirolimus (1 case) and non-sirolimus (1 case)
groups, suggesting that this is a secondary immunosup-
pression related tissue reaction that is not directly
related to sirolimus toxicity.
Sirolimus induced immunosuppression results from
the inhibition of T and B lymphocyte proliferation
through the same mechanisms as it inhibits cancer cell
proliferation. These effectsa r et h o u g h tt ob em e d i a t e d
through the rapamycin-FKPB12 complex altering the
mTOR signaling network which includes tumor sup-
pressor genes (PTEN, LKB1, TSC1, and TSC2) and
proto-oncogenes (PI3K, Akt, and eIF4E) [43]. While
the exact mechanisms of sirolimus toxicity are not
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improvement after sirolimus dose reduction provides
evidence for a dose-dependant pulmonary toxicity.
Clinically and radiologically documented pneumonitis
in kidney transplant recipients has been reported to
improve dramatically after sirolimus dose reduction
and the maintenance of lower trough levels [44]. BAL
fluid analysis in cases of the drug induced alveolitis
showed a predominance of CD4-positive lymphocytes
allowing the authors to suggest that a cell mediated
autoimmune response may be one of the factors
responsible for sirolimus induced pulmonary toxicity
[44]. Furthermore, it has been speculated that the
drug’s high affinity for plasma proteins may render sir-
olimus immunogenic as a hapten eliciting cascade of
T-cell mediated delayed type of hypersensitivity reac-
tion [18]. These hypotheses appear to capture the state
of current knowledge; however, detailed mechanisms
of sirolimus toxicity and their relationship to the spec-
trum of histological patterns of parenchymal lung dis-
ease are yet to be elucidated.
Conclusions
Our study documents that kidney transplant recipients
show a range of pulmonary neoplastic and non-neoplas-
tic lesions, which are likely associated with the type of
immunosuppressive regimen. Current mTOR inhibitor
inclusive regimens may account for decreased number
of tumors in kidney transplant recipients but also carry
a risk of pulmonary toxicity manifesting histologically by
pulmonary hemorrhage, organizing pneumonia and
other less common histological patterns.
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